MET and neoplasm: This approach requires defining the MET gene status in tumor rebiopsies from progressive lesions by thoroughly assessing the possible occurrence of its amplification or mutation as well as the overexpression of the MET receptor protein, since these dysregulations may occur as concurrent subclonal events or in a temporal sequence.